Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health

Verified sourceVerified Aug 28, 2026Updated Aug 28, 2026Funding source

Funding amount

Varies

Deadline

Nov 19, 2026

Geography

National (all U.S.)

Analyzing this grant for you…

About this grant

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Eligibility

See opportunity page for eligibility details.

Required documents

SF-424
Project narrative
Budget

Eligible organization types

Nonprofit

Official website

Always verify grant requirements directly with the funder before applying.